亿胜生物(01061.HK) 宣布,集团与复宏汉霖(02696.HK) 合作开发的重组抗血管内皮生长因子人源化单克隆抗体注射液EB12-20145P(HLX04-O)用于湿性年龄相关性黄斑变性的国际多中心III期临床研究已成功达到预设的主要研究终点。该研究结果将与中国III期临床研究共同构成关键数据,支持集团推进包括美国在内的海外市场的上市申请。此前,EB12-20145P(HLX04-O)用于...
Source Link亿胜生物(01061.HK) 宣布,集团与复宏汉霖(02696.HK) 合作开发的重组抗血管内皮生长因子人源化单克隆抗体注射液EB12-20145P(HLX04-O)用于湿性年龄相关性黄斑变性的国际多中心III期临床研究已成功达到预设的主要研究终点。该研究结果将与中国III期临床研究共同构成关键数据,支持集团推进包括美国在内的海外市场的上市申请。此前,EB12-20145P(HLX04-O)用于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.